Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 1)

v3.19.3
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2018
USD ($)
Equity_Instrument
Debt Instrument [Line Items]    
Conversion Price | $ / shares $ 10.00  
Principal Outstanding $ 19,279 $ 55,172
Discount Amount 72 16,933
Carrying Amount $ 19,207 $ 38,239
Shares Underlying Notes | Equity_Instrument 1,648 6,499
2019 Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Interest rate 10.00%  
Term of Notes 18 months  
Conversion Price | $ / shares $ 9.52  
Principal Outstanding $ 12,200  
Carrying Amount $ 12,200  
Shares Underlying Notes | Equity_Instrument [1] 1,292  
Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Principal Outstanding $ 12,200  
Carrying Amount $ 12,200  
Shares Underlying Notes | Equity_Instrument 1,292  
Principal Outstanding, Current $ 11,000  
Convertible Debentures, Current $ 11,000  
Shares Underlying Notes Current | Equity_Instrument 1,166  
Principal Outstanding, Non Current $ 1,200  
Convertible Debentures, Non Current $ 1,200  
Shares Underlying Notes Non Current | Equity_Instrument 126  
[1] The notes are convertible to Emmaus Life Sciences, Inc. shares.